Cingulate Secures Key U.S. Patent for ADHD Drug CTx-1301, Extending Exclusivity to 2042
CING sits 54% above its 52-week low of $3.16 on light trading volume (0.4× avg).
Summary
Cingulate Inc. announced the issuance of a U.S. patent for its lead ADHD drug, CTx-1301, securing its formulation and method of use through 2042, despite recent FDA regulatory setbacks.
Key Events · Product Development and Regulatory · CING
-
U.S. Patent Issued for CTx-1301
The United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,653,791, covering key aspects of CTx-1301's formulation and method of use.
-
Exclusivity Extended to 2042
The new patent strengthens Cingulate's intellectual property portfolio, extending exclusivity for CTx-1301 into December 2042.
-
Follows Recent FDA Rejection
This patent issuance occurs shortly after the FDA issued a Complete Response Letter for CTx-1301 on June 2, 2026, citing manufacturing issues, which remains a significant near-term challenge for the drug's approval.
Analysis · CING · Life Sciences
This patent issuance strengthens Cingulate's intellectual property for its lead ADHD drug candidate, CTx-1301, by extending exclusivity through December 2042. While a positive long-term development, it follows a recent FDA Complete Response Letter for CTx-1301, meaning the drug still faces regulatory hurdles before commercialization can begin. The patent secures the market position if those hurdles are overcome.
At the time of this filing, CING was trading at $4.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.